IR@PKUHSC  > 北京大学药学院
学科主题药学
Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas
Li, Liyu; Hou, Jianjun; Liu, Xinjie; Guo, Yujia; Wu, Yun; Zhang, Lihe; Yang, Zhenjun
关键词Nucleolin As1411 Liposomes Sirna Delivery Melanomas Therapeutic Effect
刊名BIOMATERIALS
2014-04-01
DOI10.1016/j.biomaterials.2014.01.019
35期:12页:3840-3850
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Engineering, Biomedical ; Materials Science, Biomaterials
研究领域[WOS]Engineering ; Materials Science
关键词[WOS]PLGA-PEG NANOPARTICLES ; PROSTATE-CANCER CELLS ; DRUG-DELIVERY ; ANTIPROLIFERATIVE ACTIVITY ; THERAPY ; SYSTEM ; GROWTH ; OLIGONUCLEOTIDES ; TRANSFECTION ; CYTOTOXICITY
英文摘要

BRAF gene mutation is found in more than 60% of malignant melanomas, which are difficult to treat. In this study, a new tumor-targeting liposome was developed to deliver anti-BRAF siRNA (siBraf) for the treatment of melanomas. Nucleolin is overexpressed on the surface of cancer cells. AS1411, an aptamer showing specific binding to nucleolin, was conjugated to PEGylated cationic liposome as the targeting probe ASLP (AS1411 PEG-liposome). The ASLP/siRNA complex was formed through electrostatic interaction between ASLP and siRNA. The binding of A51411 to the surface of PEGylated liposomes was confirmed by gel electrophoresis and capillary electrophoresis. Real-time PCR and Western blot analysis showed that ASLP/siBraf exhibited strong silencing activity of BRAE gene. The much higher accumulation of the siRNA in tumor cells comparing with normal cells indicated that ASLP displayed excellent tumortargeting capability. Notably, ASLP/siBraf showed significant silencing activity in A375 tumor xenograft mice and inhibited the melanoma growth. These results suggested that the new nucleolin-targeted siRNA delivery system by AS1411 may have the potential for the treatment of melanoma. (c) 2014 Elsevier Ltd. All rights reserved.

语种英语
WOS记录号WOS:000332431700013
项目编号2012CB720604 ; 2012AA022501 ; 20092001 ; 2009ZX09310-001
资助机构National Basic Research Program of China ; NSFC projects ; New Drug RD
引用统计
被引频次:68[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54806
专题北京大学药学院
北京大学药学院_药物化学系
北京大学第二临床医学院_消化科
作者单位Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Li, Liyu,Hou, Jianjun,Liu, Xinjie,et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas[J]. BIOMATERIALS,2014,35(12):3840-3850.
APA Li, Liyu.,Hou, Jianjun.,Liu, Xinjie.,Guo, Yujia.,Wu, Yun.,...&Yang, Zhenjun.(2014).Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas.BIOMATERIALS,35(12),3840-3850.
MLA Li, Liyu,et al."Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas".BIOMATERIALS 35.12(2014):3840-3850.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Liyu]的文章
[Hou, Jianjun]的文章
[Liu, Xinjie]的文章
百度学术
百度学术中相似的文章
[Li, Liyu]的文章
[Hou, Jianjun]的文章
[Liu, Xinjie]的文章
必应学术
必应学术中相似的文章
[Li, Liyu]的文章
[Hou, Jianjun]的文章
[Liu, Xinjie]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。